Literature DB >> 10473669

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.

P Delerive1, F Martin-Nizard, G Chinetti, F Trottein, J C Fruchart, J Najib, P Duriez, B Staels.   

Abstract

Endothelin-1 (ET-1), a 21-amino acid vasoactive peptide mainly produced by vascular endothelial cells, is involved in the regulation of vascular tone and smooth muscle cell proliferation. Peroxisome proliferator-activated receptors (PPARs), key players in lipid and glucose metabolism, have been implicated in metabolic disorders that are predisposing to atherosclerosis. Because of the potential role of ET-1 in vascular disorders such as hypertension and atherosclerosis, we investigated the regulation of ET-1 expression by PPAR activators. Western blot and reverse transcription-polymerase chain reaction analyses demonstrated that both PPARalpha and PPARgamma are expressed in human coronary artery endothelial cells as well as in endothelial cell lines such as HMEC-1 and ECV304. In bovine aortic endothelial cells and HMEC-1 cells, both PPARalpha and PPARgamma ligands inhibited thrombin-induced ET-1 secretion, whereas basal ET-1 secretion was only slightly suppressed. Reverse transcription-polymerase chain reaction experiments showed that this inhibition of ET-1 production occurs at the gene expression level. Using transient transfection assays, we demonstrated that PPARs downregulate thrombin-activated transcription of the human ET-1 promoter. Transactivation studies with c-Jun and c-Fos expression plasmids indicated that PPARs negatively interfere with the activator protein-1 signaling pathway, which mediates thrombin activation of ET-1 gene transcription. Furthermore, electrophoretic mobility shift assays demonstrated that PPAR activators reduce the thrombin-stimulated binding activity of bovine aortic endothelial cell nuclear extracts as well as c-Jun binding to an activator protein-1 consensus site. Taken together, these data indicate that (1) both PPARalpha and PPARgamma are expressed in human vascular endothelial cells and (2) PPAR activators inhibit thrombin-induced ET-1 biosynthesis, indicating a novel role for PPARs in vascular endothelial function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473669     DOI: 10.1161/01.res.85.5.394

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  108 in total

Review 1.  Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.

Authors:  Luther T Clark
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

2.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

Authors:  G Martin; H Duez; C Blanquart; V Berezowski; P Poulain; J C Fruchart; J Najib-Fruchart; C Glineur; B Staels
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 3.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 4.  Fibrates for treatment of the metabolic syndrome.

Authors:  Kevin C Maki
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

Review 5.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

6.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

Review 7.  Role of endothelin-1 in hypertension.

Authors:  Marc Iglarz; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 8.  Pleiotropic effects of fibrates.

Authors:  Giulia Chinetti-Gbaguidi; Jean Charles Fruchart; Bart Staels
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 9.  Are thiazolidinediones good or bad for the heart?

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

10.  Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Protects Blood-Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing the Levels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway.

Authors:  Yonglin Zhao; Xing Wei; Jinning Song; Ming Zhang; Tingqin Huang; Jie Qin
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.